Skip to main content

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Targeted Oncology volume 13, pages 227–234 (2018)Cite this article

Abstract

Background

Ramucirumab—alone or combined with paclitaxel—represents one of the main options for patients failing first-line treatment for advanced gastric cancer.

Objective

The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the “real-life setting”.

Patients and Methods

Patients from 25 Italian hospitals started therapy consisting of ramucirumab 8 mg/kg i.v. d1,15q28 with or without paclitaxel 80 mg/m2 i.v. d1,8,15q28. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results

One hundred sixty-seven patients with disease progression on first-line therapy received ramucirumab as monotherapy (10%) or combined with paclitaxel (90%). Median treatment duration was 4 months (1–17 months). Global incidence of grade (G) 3–4 toxicity was 9.6%, and for neutropenia 5.4%; treatment was discontinued due to toxicity in 3% of patients. The most frequent adverse events (AE) were G1–2 fatigue (27.5%), G1–2 neuropathy (26.3%), and G1–2 neutropenia (14.9%). ORR was 20.2%. Stable disease was observed in 39.2% of patients, with a disease control rate of 59.4%. With a median follow-up of 11 months, median PFS was 4.3 months (95% confidence interval [CI] 4.1–4.7), whereas median OS was 8.0 months (95% CI: 7.09–8.9). In a multivariate analysis, ECOG performance status <1 or ≥1 (HR 1.13, 95% CI 1.0–1.27, p = 0.04) and the presence versus absence of peritoneal metastases (HR 1.57, 95% CI 1.63–2.39, p = 0.03) were independent poor prognostic factors.

Conclusions

These “real-life” efficacy data on ramucirumab treatment are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330–44. https://doi.org/10.1016/j.ejca.2014.01.029.

    Article  PubMed  Google Scholar 

  2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.

    CAS  Article  PubMed  Google Scholar 

  3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. https://doi.org/10.1056/NEJMoa010187.

    CAS  Article  PubMed  Google Scholar 

  4. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. https://doi.org/10.1200/JCO.2010.33.0597.

    CAS  Article  PubMed  Google Scholar 

  5. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64. https://doi.org/10.1016/S0140-6736(16)30354-3.

    Article  PubMed  Google Scholar 

  6. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064. https://doi.org/10.1002/14651858.CD004064.pub3.

    Google Scholar 

  7. Cho YH, Yoon SY, Kim SN. Irinotecan monotherapy versus irinotecan-based combination as second-line chemotherapy in advanced gastric cancer: a meta-analysis. Cancer Res Treat. 2017;49(1):255–62. https://doi.org/10.4143/crt.2015.452.

    Article  PubMed  Google Scholar 

  8. Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol. 2015;8(4):189–205. https://doi.org/10.1177/1756283X15585468.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. https://doi.org/10.1016/S0140-6736(13)61719-5.

    CAS  Article  PubMed  Google Scholar 

  10. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.

    CAS  Article  PubMed  Google Scholar 

  11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

    CAS  Article  PubMed  Google Scholar 

  12. Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016;19(3):927–38. https://doi.org/10.1007/s10120-015-0559-z.

    CAS  Article  PubMed  Google Scholar 

  13. Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer. 2016;114(4):381–7. https://doi.org/10.1038/bjc.2015.452.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8. https://doi.org/10.1200/JCO.2011.39.4585.

    CAS  Article  PubMed  Google Scholar 

  15. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86. https://doi.org/10.1016/S1470-2045(13)70549-7.

    CAS  Article  PubMed  Google Scholar 

  16. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14. https://doi.org/10.1016/j.ejca.2011.06.002.

    CAS  Article  PubMed  Google Scholar 

  17. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44. https://doi.org/10.1200/JCO.2012.48.5805.

    CAS  Article  PubMed  Google Scholar 

  18. Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9(9):e108940. https://doi.org/10.1371/journal.pone.0108940.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Roviello G, Pacifico C, Polom K, Roviello F, Generali D. Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status. Ann Oncol. 2017;28(3):665–6. https://doi.org/10.1093/annonc/mdw657.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Maria Di Bartolomeo and Ferdinando De Vita contributed equally to this work.

Affiliations

  1. Department of Medical Oncology, Fondazione IRCCS Istituto Tumori, via G. Venezian, 1, 20133, Milan, Italy

    Maria Di Bartolomeo, Monica Niger, Rosa Berenato, Filippo Pietrantonio, Federica Morano & Maria Antista

  2. University of Campania “Luigi Vanvitelli” – School of Medicine, Naples, Italy

    Giuseppe Tirino, Angelica Petrillo, Maria Maddalena Laterza, Jole Ventriglia & Ferdinando De Vita

  3. Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy

    Sara Lonardi

  4. Oncology Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

    Lorenzo Fornaro

  5. Department of Oncology and Haematology, Oncology Unit, Faenza Hospital AUSL Romagna, Ravenna, Italy

    Stefano Tamberi

  6. Medical Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Elisa Giommoni

  7. Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy

    Alberto Zaniboni

  8. Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, Italy

    Lorenza Rimassa

  9. Division of Medicine and Medical Oncology, Azienda Istituti Ospitalieri, Cremona, Italy

    Gianluca Tomasello

  10. Department of Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

    Teodoro Sava

  11. Fondazione Istituto G. Giglio di Cefalu, Palermo, Italy

    Massimiliano Spada

  12. Medical Oncology Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

    Tiziana Latiano

  13. Department of Oncology, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy

    Alessandro Bittoni

  14. Azienda Ospedaliera della Valtellina e della Valchiavenna, Sondrio, Italy

    Alessandro Bertolini

  15. Medical Oncology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy

    Ilaria Proserpio

  16. Department of Hematology and Oncology, Niguarda Cancer Center, Niguarda, Milan, Italy

    Katia Bruna Bencardino

  17. Medical Oncology Unit, Azienda Ospedaliera-Ospedali Riuniti Marche Nord, Pesaro, Italy

    Francesco Graziano

  18. Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy

    Giordano Beretta

  19. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy

    Salvatore Galdy

  20. Medical Oncology Department, University of Rome Sapienza, Rome, Italy

    Simone Scagnoli

  21. Medical Oncology and Hematology Department, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

    Andrea Spallanzani

  22. Unit of Medical Oncology, San Gerardo Hospital, Monza, Italy

    Raffaella Longarini

Authors
  1. Maria Di Bartolomeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Niger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Tirino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angelica Petrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosa Berenato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Maddalena Laterza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Filippo Pietrantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Federica Morano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Antista
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sara Lonardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lorenzo Fornaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Stefano Tamberi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Elisa Giommoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Alberto Zaniboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lorenza Rimassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Gianluca Tomasello
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Teodoro Sava
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Massimiliano Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tiziana Latiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Alessandro Bittoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Alessandro Bertolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Ilaria Proserpio
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Katia Bruna Bencardino
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Francesco Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Giordano Beretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Salvatore Galdy
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Jole Ventriglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Simone Scagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Andrea Spallanzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Raffaella Longarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Ferdinando De Vita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Di Bartolomeo.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of Interest

Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza Rimassa, Gianluca Tomasello, Teodoro Sava, Massimiliano Spada, Tiziana Latiano, Alessandro Bittoni, Alessandro Bertolini, Ilaria Proserpio, Katia Bruna Bencardino, Francesco Graziano, Giordano Beretta, Salvatore Galdy, Jole Ventriglia, Simone Scagnoli, Andrea Spallanzani, Raffaella Longarini, and Ferdinando De Vita declare that they have no conflict of interest that might be relevant to the content of this manuscript.

Ethical Approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di Bartolomeo, M., Niger, M., Tirino, G. et al. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Targ Oncol 13, 227–234 (2018). https://doi.org/10.1007/s11523-018-0562-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-018-0562-5